Pulse Biosciences develops bioelectric medicine technology based on its proprietary nPulse platform, which uses nanosecond pulsed field ablation energy to deliver nanosecond electrical pulses for non-thermal cell clearing. Company news commonly centers on the nPulse Cardiac Catheter System for atrial fibrillation, clinical study disclosures, feasibility data, and presentations at electrophysiology and healthcare conferences.
Recurring updates also cover the company's work in selected applications such as surgical soft tissue ablation, investor presentations and analyst events, executive leadership changes, operating and financial results, governance matters, and capital-structure disclosures related to its common stock and financing programs.
Pulse Biosciences (PLSE) will report third-quarter 2026 financial results and business updates after market close on November 5, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET. A live and recorded webcast will be available on the company's investor website.
Pulse Biosciences (PLSE) announced a commercial and clinical partnership with the Clayman Thyroid Center for benign thyroid nodule treatment.
The center, at the Hospital for Endocrine Surgery in Tampa, Florida, is now treating patients with the nPulse Vybrance Percutaneous Electrode System under Pulse Biosciences' controlled market development strategy. It is the only site in the Tampa Bay Area offering nPulse technology for symptomatic benign thyroid nodules.
The clinical collaboration will collect real-world patient outcomes and include formal studies evaluating nanosecond pulsed field ablation, which uses ultra-short bursts of electrical energy, for benign thyroid nodules. Pulse Biosciences expects the work to add to the evidence supporting the Vybrance System and described the partnership as a foundation for expanded access.
Pulse Biosciences (PLSE) issued inducement stock options covering up to 5,700 common shares to two new employees on October 8, 2026.
The options have an exercise price of $49.98 per share and vest over four years, with one-quarter of each award vesting annually, subject to continued employment. The independent Compensation Committee approved the awards under Nasdaq Listing Rule 5635(c)(4). They were issued outside the 2017 Equity Incentive Plan, under the terms of the 2017 Inducement Equity Incentive Plan and individual award agreements.
Pulse Biosciences (PLSE) will feature its nPulse technology at the International Ventricular Arrhythmias Symposium in New York on October 9–10, 2026. The presentation will cover preclinical applications of two prototype endocardial catheters, designed for use inside the heart to explore potential treatment of ventricular arrhythmias, or abnormal heart rhythms.
Jacob Koruth, MD, will present “Recent Advances in PFA of Ventricular Arrhythmias” on October 10 from 5:20–5:30 p.m. at the New York Marriott at the Brooklyn Bridge, Room X, during the “Pulse Field Ablation of Ventricular Arrhythmias – Part II” session.
Pulse Biosciences (PLSE) reached its enrollment target of 164 evaluable patients in the NANOPULSE-AF pivotal study of its nPulse Cardiac Catheter System.
The study evaluates the system for atrial fibrillation treatment and enrolled patients across 15 clinical sites. Pulse Biosciences said enrollment reached the target three months ahead of its original nine-month timeline. Patients will continue to be followed through study completion.
National principal investigator Vivek Reddy described investigator interest and steady enrollment after sites began participating. Study investigator Shephal Doshi described his early experience with the catheter's procedural workflow as straightforward and efficient, while saying he looks forward to the study results and further clinical experience.
Pulse Biosciences (PLSE) completed enrollment of 100 patients in the PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for symptomatic benign thyroid nodules.
The study, originally designed for 50 patients, was expanded to 100, with all participants enrolled across three U.S. sites: Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine in approximately 12 months. The first patient enrolled completed the final 12-month follow-up visit in August at Sarasota Memorial Health Care System under the supervision of Ralph P. Tufano, MD. Pulse Biosciences develops the nPulse technology using proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) energy, which is being evaluated in this study as a treatment option for benign thyroid nodules.
The company plans to present preliminary PRECISE-BTN data at an upcoming medical society conference and expects to report full data after all patients complete their 12‑month follow-up.
Pulse Biosciences (PLSE) granted equity inducement stock options to two new employees on September 2, 2026, under its 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards cover an aggregate of 2,200 shares of common stock, with an exercise price of $52.68 per share, equal to the closing price on the grant date. The options vest over four years on a time-based schedule, with one quarter of each award vesting annually, subject to continued employment. The grants were approved by the company’s independent Compensation Committee and remain subject to the plan’s terms and individual award agreements.
Pulse Biosciences (Nasdaq: PLSE) reported that its Board’s Compensation Committee granted equity inducement awards to five new employees under the 2017 Inducement Equity Incentive Plan, consistent with Nasdaq Listing Rule 5635(c)(4). The options, approved and issued on August 13, 2026, cover up to 16,950 shares of common stock in aggregate.
The stock options have an exercise price of $44.92 per share, equal to the closing price on August 13, 2026. Each award vests over four years, with 25% vesting annually, subject to continued employment. The options are governed by the 2017 Inducement Equity Incentive Plan and individual award agreements.
Pulse Biosciences (Nasdaq: PLSE) reported Q2 2026 revenue of $0.4 million from its controlled commercial launch and a GAAP net loss of $24.7 million versus $19.2 million a year earlier. GAAP operating costs rose to $25.7 million, driven mainly by higher clinical and compensation expenses.
Cash and cash equivalents were $101.6 million at June 30, 2026, aided by $46.8 million in Q2 net proceeds from an at-the-market equity program and additional post‑quarter proceeds. NANOPULSE-AF, the U.S. pivotal study of the nPulse Cardiac Catheter System for atrial fibrillation, surpassed the halfway enrollment mark and expanded its target to 164 evaluable patients while still aiming to complete enrollment by early Q4 2026.
The company continued enrollment in the NANOCLAMP-AF pivotal surgical AF study, advanced the PRECISE-BTN benign thyroid nodule trial (expanded to 100 patients and nearing full enrollment), and progressed a first‑in‑human cancer feasibility study. Pulse Biosciences reiterated plans to seek CE Marks for its catheter and surgical AF systems by late 2026, with potential approvals anticipated by mid‑2027.
Pulse Biosciences (Nasdaq: PLSE) will participate in Canaccord Genuity’s 46th Annual Growth Conference in Boston, MA. Company management is scheduled to present in a fireside chat on Tuesday, August 11, at 2:30 p.m. ET. A live and recorded webcast will be accessible via the “Events Calendar and Presentations” section of the company’s investor relations website.